BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.…
BrainsWay Ltd (BRSYF) (Q3 2026) Earnings Call Highlights: Revenue Jumps 34% as Margins Expand ...
BrainsWay (NASDAQ: BWAY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 129 employees.
The shares were at 8.480 USD on 20 November 2026, up 7.5% over 52 weeks. Its 52-week range is 7.135 USD to 17.40 USD: the price is 51.3% below the high and 18.9% above the low.
At a market capitalisation of 341.35M USD, it trades at 35.3 times trailing earnings and 17.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 38% for BWAY.
BrainsWay reports return on equity of 10.4%, an operating margin of 12.5% and revenue up 35.4% year over year.
It holds more cash than debt, a net cash position of 54.98M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 19.27 USD is 127.2% above the current price. The next earnings report is expected on 10 March 2027.